Acellular dermal matrices refer to biologic products derived from human or porcine dermis that have had resident cellular components removed, leaving behind an intact collagen-elastin matrix. They are used primarily in plastic and reconstructive surgery as a tissue grafting material to support and augment soft tissue repair and regeneration. Common procedures where acellular dermal matrices are used include breast reconstruction, treatment of abdominal hernia, lip and cheek augmentation, vaginal prolapse repair and others. The matrices are placed under or around damaged soft tissue to provide scaffolding for new tissue ingrowth and vascularization. The global acellular dermal matrices market is estimated to be valued at US$ 8.8 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Growing incidence of burns, traumatic injuries and associated soft tissue defects are a key driver favoring growth of the acellular dermal matrices market.According to the World Health Organization, burns claim around 180,000 lives annually across the globe. Soft tissue injuries account for 20-30% cases among burn patients requiring tissue replacements and grafts. Rise in elderly population who are at higher risk of burns, injuries and soft tissue defects due to decreased mobility and cognitive function is also contributing to market growth. Moreover, growing obesity rates increasing the need for body contouring procedures such as breast reconstruction surgery, tummy tucks and others utilizing acellular dermal matrices is expected to further support market expansion over the forecast period.

However, factors such as high costs associated with acellular dermal matrices, lack of reimbursement in developing regions and stringent regulations governing their approval can restrain market growth to a certain extent. Further, risk of diseased transmission through allografts and possibility of immune reactions are major challenges faced by market players. Manufacturers are focusing on developing cost-effective bioengineered dermal substitutes and tissues to strengthen their market position. Overall, increasing awareness regarding cosmetic and reconstructive procedures and rising medical tourism in developing countries is anticipated to create new opportunities for players operating in the global acellular dermal matrices market in the coming

SWOT Analysis

Strength: Acellular dermal matrices offer biologically similar substitutes for human dermis connective tissue during wound healing and soft tissue reconstruction while avoiding donor site morbidity. They provide a scaffold on which new collagen production and neovascularization can occur. Their acellular nature reduces risks of disease transmission or immune rejection.

Weakness: Their high manufacturing costs impact pricing and market access in certain regions. Limited long-term clinical data on outcomes and durability compared to autograft tissues could dampen adoption rates.

Opportunity: Growing geriatric populations prone to age-related wounds, burns and surgical site complications drive the need for dermal substitutes. Wider reimbursements would expand the addressable market regionally.

Threats: Strict regulations for cosmetic and reconstructive procedures could delay product approvals. Alternative tissue-engineered skin and dermal substitutes from new market entrants present competitive threats over time.

Key Takeaways

The Global Acellular Dermal Matrices Market Size is expected to witness high growth.

Regionally, North America dominates the market currently due to favorable reimbursement scenarios and a high prevalence of burn injuries and cosmetic/reconstructive surgeries. The Asia Pacific region is anticipated to grow at the fastest rate during the forecast period due to rapid economic development, rising medical tourism, and growing awareness.

Key players operating in the acellular dermal matrices market are Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc. Among these, 4SC AG, CellCentric Ltd., and Celleron Therapeutics Ltd. are focused on clinical-stage epigenetic modifier programs in oncology. Bristol-Myers Squibb Company and Oryzon Genomics S.A. have pre-clinical or clinical stage programs targeting solid and hematological cancers.  

Get More Insights Here

https://www.trendingwebwire.com/acellular-dermal-matrices-market-size-share-growth-outlook-2023/